Leukotriene antagonists: patent highlights 1996 - 1998

Antagonists of leukotriene D-4 (LTD4) have shown clinical efficacy in the treatment of asthma while efficacy with antagonists of leukotriene B-4 (LTB4) has yet to be demonstrated. The development of dual mediators possessing either histamine (H-1), thromboxane (TXA(2)), or serine protease activity coupled with leukotriene antagonist activity offers a new direction of research, one which offers the greatest potential in discovering a superior agent for the treatment of allergic and inflammatory diseases.